Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Cutan Pathol ; 46(2): 159-161, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30468020

RESUMEN

We report a case of disseminated Trichosporon asahii in a patient on systemic antifungal therapy who presented with multiple cutaneous nodules suggestive of fungal infection. Histologic features resembled neutrophilic eccrine hidradenitis but staining with periodic acid-Schiff and Gomori methenamine silver confirmed the clinical diagnosis. This case highlights the importance of maintaining suspicion for trichosporonosis and contextualizing histologic findings within the underlying clinical picture.


Asunto(s)
Dermatomicosis , Leucemia-Linfoma Linfoblástico de Células Precursoras , Tricosporonosis , Adolescente , Dermatomicosis/diagnóstico , Dermatomicosis/tratamiento farmacológico , Dermatomicosis/patología , Humanos , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Tricosporonosis/diagnóstico , Tricosporonosis/tratamiento farmacológico , Tricosporonosis/patología
3.
Pediatr Dermatol ; 35(4): e235-e236, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29766561

RESUMEN

Indications for everolimus and other drugs within the mammalian target of rapamycin inhibitor class have recently expanded to include tuberous sclerosis complex. Everolimus is generally well tolerated, but it is important for physicians to identify and manage associated cutaneous adverse effects. We report the first case of a child developing erythema nodosum while undergoing everolimus therapy.


Asunto(s)
Antineoplásicos/efectos adversos , Eritema Nudoso/inducido químicamente , Everolimus/efectos adversos , Esclerosis Tuberosa/tratamiento farmacológico , Adolescente , Antineoplásicos/uso terapéutico , Everolimus/uso terapéutico , Femenino , Humanos , Piel/patología
4.
J Cell Physiol ; 226(7): 1868-78, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21506117

RESUMEN

5-Fluorouracil (5-FU) is a classic chemotherapeutic drug that has been widely used for breast cancer treatment. Although aberrant expression of protein-coding genes was observed after 5-FU treatment, the regulatory mechanism remains poorly understood. MicroRNAs (miRNAs) are a newly identified class of small regulatory RNAs which play an important role in gene regulation at the post-transcriptional levels. Recent evidence suggests an important role of miRNAs in initiation, progression, and metastasis of human cancers. In this study, using a combined advanced microarray and quantitative real-time PCR (qRT-PCR) technology, we show that 5-FU significantly alters the global expression profile of miRNAs in vitro. After 48 h of treatment with a low dose (0.01 µM), 42 miRNAs were differentially expressed in MCF-7 breast cancer cell line. Of these, 23 miRNAs were up-regulated with up to 4.59-fold changes, while 19 were down-regulated with up to 1.89-fold changes. A majority of these miRNAs are associated with cancer development, progression, and metastasis. Target prediction and GO analysis suggest that these differentially expressed miRNAs potentially target many oncogenes, tumor suppressor genes and genes related to programmed cell death, activation of immune response, and cellular catabolic processes.


Asunto(s)
Antimetabolitos Antineoplásicos/farmacología , Neoplasias de la Mama/genética , Fluorouracilo/farmacología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , MicroARNs/metabolismo , Neoplasias de la Mama/inmunología , Neoplasias de la Mama/patología , Línea Celular Tumoral , Femenino , Perfilación de la Expresión Génica/métodos , Humanos , Análisis de Secuencia por Matrices de Oligonucleótidos , Reproducibilidad de los Resultados , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de Tiempo
5.
Cancer Genomics Proteomics ; 7(5): 261-77, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20952761

RESUMEN

This study reports for the first time the microRNA expression profile of human breast cancer MCF-7 cells and the effect of green tea. Although hundreds of miRNAs have been identified in humans, only a small proportion (25.6%) of miRNAs are expressed in MCF-7 cells. Low concentration treatment with Polyphenon-60 significantly alters the miRNA expression profile in MCF-7 cells. Twenty three miRNAs have been identified with differential expression after a 48 h treatment with 10 µg/ml Polyphenon-60 (green tea extract). These miRNAs include miR-21 and miR-27 that were found to be down-regulated following treatment with green tea. These two miRNAs have previously been identified as being overexpressed in MCF-7 breast cancer cells, with miR-21 specifically implicated in down-regulating the tumor suppressor gene, tropomyosin-1. This data supports the hypothesis that Polyphenon-60-induced modification of the breast cancer miRNA expression profile contributes to the efficacy of green tea treatment. The resulting decrease in carcinogenesis is further supported by the altered miRNA regulation of potential oncogenes and tumor-suppressor genes.


Asunto(s)
Antineoplásicos/farmacología , Neoplasias de la Mama/genética , Camellia sinensis , Catequina/análogos & derivados , MicroARNs/genética , Extractos Vegetales/farmacología , Biomarcadores de Tumor/metabolismo , Catequina/genética , Catequina/farmacología , Línea Celular Tumoral , Femenino , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Genes Supresores de Tumor , Humanos , Oncogenes , Reacción en Cadena de la Polimerasa , Tropomiosina/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA